



BIBLIOGRAPHY

GLP-1-RA Drugs + Lifestyle Medicine for Weight Loss Webinar February 9, 2024

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2032183>

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2206038>

Wadden, T.A., Chao, A.M., Machineni, S. et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. *Nat Med* 29, 2909–2918 (2023). <https://doi.org/10.1038/s41591-023-02597-w> Specifically:

<https://www.nature.com/articles/s41591-023-02597-w#Fig2>

Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzone KA, Jay M. Obesity Management in Adults: A Review. *JAMA*. 2023;330(20):2000–2015. doi:10.1001/jama.2023.19897

<https://jamanetwork.com/journals/jama/article-abstract/2812316>

Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD, Pronk NP. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. *J Am Diet Assoc*. 2007 Oct;107(10):1755-67. doi: 10.1016/j.jada.2007.07.017. PMID: 17904936.

<https://pubmed.ncbi.nlm.nih.gov/17904936/>

Levi J, Wang J, Venter F, Hill A. Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. *Obesity* (Silver

Spring). 2023 May;31(5):1270-1279. doi: 10.1002/oby.23725. Epub 2023 Feb 23. PMID: 36815242.

<https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23725>

Kim JE, O'Connor LE, Sands LP, Slebodnik MB, Campbell WW. Effects of dietary protein intake on body composition changes after weight loss in older adults: a systematic review and meta-analysis. *Nutr Rev*. 2016 Mar;74(3):210-24. doi: 10.1093/nutrit/nuv065. Epub 2016 Feb 16. PMID: 26883880; PMCID: PMC4892287.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892287/pdf/nuv065.pdf>

Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. *Nutrients*. 2018 Mar 29;10(4):423. doi: 10.3390/nu10040423. PMID: 29596307; PMCID: PMC5946208.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946208/pdf/nutrients-10-00423.pdf>

Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metab*. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/>

O'Mary, Lisa. FDA Evaluating Three Side Effects Reported With Weight Loss Drugs. *Medscape Health News*, January 5, 2024.

<https://www.medscape.com/s/viewarticle/fda-investigates-three-side-effects-reported-weight-loss-2024a10000e4>

Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. January 11, 2024.

<https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type>

Cembalest, Michael. The Fats Dominoes: the impact of weight loss drugs on equity markets. From JP Morgan Eye on the Market: Pillow Talk. January 1, 2024

<https://assets.jpmprivatebank.com/content/dam/jpm-pb-aem/global/en/documents/eotm/outlook-2024.pdf#page=32>

Wang, W., Volkow, N.D., Berger, N.A. et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. *Nat Med* (2024).

<https://doi.org/10.1038/s41591-023-02672-2>.

Saumoy M, Gandhi D, Buller S, Patel S, Schneider Y, Cote G, Kochman ML, Thiruvengadam NR, Sharaiha RZ. Cost-effectiveness of endoscopic, surgical and pharmacological obesity

therapies: a microsimulation and threshold analyses. *Gut*. 2023 Nov 24;72(12):2250-2259. doi: 10.1136/gutjnl-2023-330437. PMID: 37524445.

<https://gut.bmj.com/content/72/12/2250>

Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. *J Clin Invest*. 2024 Jan 16;134(2):e175634. doi: 10.1172/JCI175634. PMID: 38226625; PMCID: PMC10786682.

<https://www.jci.org/articles/view/175634>

Winzeler B, Sailer CO, Coyne D, Zanchi D, Vogt DR, Urwyler SA, Refardt J, Christ-Crain M. A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia. *J Clin Invest*. 2021 Oct 15;131(20):e151800. doi: 10.1172/JCI151800. PMID: 34473645; PMCID: PMC8516458.

<https://pubmed.ncbi.nlm.nih.gov/34473645/>

What is Food is Medicine, and how can it help transform healthcare systems toward more holistic, cost-effective care? World Economic Forum. Health and Healthcare. January 16, 2024.

<https://www.weforum.org/agenda/2024/01/our-lifestyles-are-making-us-sick-how-food-as-medicine-can-help/>

Hall KD, Ayuketah A, Brychta R, Cai H, Cassimatis T, Chen KY, Chung ST, Costa E, Courville A, Darcey V, Fletcher LA, Forde CG, Gharib AM, Guo J, Howard R, Joseph PV, McGehee S, Ouwerkerk R, Raising K, Rozga I, Stagliano M, Walter M, Walter PJ, Yang S, Zhou M. Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. *Cell Metab*. 2019 Jul 2;30(1):67-77.e3. doi: 10.1016/j.cmet.2019.05.008. Epub 2019 May 16. Erratum in: *Cell Metab*. 2019 Jul 2;30(1):226. Erratum in: *Cell Metab*. 2020 Oct 6;32(4):690. PMID: 31105044; PMCID: PMC7946062.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946062/>

Visaria A, Sindhu T, Dharamdasani T. OR10-01 Discordance Between Body Mass Index and Dual-energy X-ray Absorptiometry Based Adiposity Measures Among United States Adults. *J Endocr Soc*. 2023 Oct 5;7(Suppl 1):bvad114.007. doi: 10.1210/jendso/bvad114.007. PMCID: PMC10555121.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555121/>